Twenty Questions Patients Ask About Multiple Myeloma Treatment in China

Decisions about myeloma rarely arrive all at once. Diagnosis brings questions about tests and urgency; treatment introduces concerns about side effects, transplant, work, and cost. Patients considering China must also connect the proposed treatment to care in their home country. These answers explain what to clarify at each stage. An overseas approval or published study does not establish that a Chinese hospital can provide the same product for the same indication.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Multiple myeloma is a cancer of plasma cells. Bone damage is one possible consequence, alongside kidney problems, reduced blood-cell production, and impaired immunity. An operation can stabilize a threatened fracture or address an unstable spine, but removing one painful area does not eliminate abnormal plasma cells elsewhere. Treatment usually requires medicines that act throughout the body. Describe fatigue, infections, changes in urine output, and other symptoms as well as bone pain, so the assessment does not stop at the first abnormal X-ray. The distinction also explains why successful orthopedic treatment can be followed by continuing hematology care. National Cancer Institute patient overview
An MRD-negative result means no residual disease was detected by a particular test, at its stated sensitivity, in the sample examined at that time. It is valuable response information, but it is not a permanent guarantee about every site in the body. Sample quality, the test used, the duration of negativity, and disease outside the marrow can affect interpretation. Whether treatment can be reduced on this basis depends on the actual regimen and supporting evidence. Keep the method and sensitivity with the report rather than recording only “negative.” Results from different hospitals are most meaningful when the methods and clinical circumstances are sufficiently comparable. IMWG response and MRD criteria
Trials can be appropriate at different stages. Their value depends on the research question, established alternatives, and the patient's circumstances. Ask about allocation to groups, which elements remain experimental, additional tests, time near the hospital, payment responsibilities, and care after withdrawal. A registry entry confirms that a study exists; it does not prove that a particular center currently has an available place. Formal screening can also exclude someone because of organ function, previous target-directed therapy, or timing requirements. Patients should understand these points before consenting. Declining or leaving a study should lead to a discussion of reasonable continuing care, not pressure to accept terms that remain unclear. NCI explanation of informed consent

Quick answer

Full guide

1. Is myeloma a bone cancer that can be removed with surgery?

Multiple myeloma is a cancer of plasma cells. Bone damage is one possible consequence, alongside kidney problems, reduced blood-cell production, and impaired immunity. An operation can stabilize a threatened fracture or address an unstable spine, but removing one painful area does not eliminate abnormal plasma cells elsewhere. Treatment usually requires medicines that act throughout the body. Describe fatigue, infections, changes in urine output, and other symptoms as well as bone pain, so the assessment does not stop at the first abnormal X-ray. The distinction also explains why successful orthopedic treatment can be followed by continuing hematology care. National Cancer Institute patient overview

2. Does finding a monoclonal protein mean treatment must start immediately?

No single protein result determines that decision. Monoclonal gammopathy of undetermined significance, smoldering myeloma, and active myeloma have different management pathways. The team combines marrow findings, free light chains, imaging, and attributable organ damage to establish the category. Options for selected high-risk smoldering disease have also changed: the United States approved subcutaneous daratumumab for adults with high-risk smoldering myeloma in 2025. That decision does not apply to every person with a monoclonal protein, and it does not confirm the same indication in China. Lack of pain is not a substitute for scheduled monitoring or for checking whether a myeloma-defining event is present. FDA approval notice

3. Why are blood tests, a marrow examination, and imaging all needed?

They answer different questions. Blood and urine protein studies help identify markers that can be followed over time. Marrow examination assesses abnormal plasma cells and supplies material for genetic testing. Imaging checks for focal bone disease, fracture risk, and disease outside the marrow. One reassuring test does not automatically cancel an abnormal finding elsewhere, and a bone-density scan does not replace appropriate myeloma imaging. Before traveling, send existing reports and original image files to the receiving team and ask which missing information would change management. This can reduce avoidable duplication while preserving investigations needed to make a safe decision. NICE diagnostic recommendations

4. Does “high risk” on my report mean treatment will not help?

High risk describes an increased likelihood of less durable disease control in a defined group; it does not mean there are no worthwhile treatments. The term may refer to genetic abnormalities, disease features, or the way myeloma behaves during treatment. Different classification systems are not interchangeable. Ask which finding produced the label and whether it changes the recommended initial regimen, transplant discussion, or follow-up. Frailty, kidney dysfunction, and infection can also affect what a person can tolerate, but these issues are distinct from tumor genetics. Separating them makes the conversation more useful than treating every concern as one undefined category of “poor prognosis.” International high-risk myeloma consensus

5. Is a four-drug initial regimen always better than a three-drug regimen?

Adding a medicine can improve disease control in an appropriate setting, but the benefit must be weighed against infection, low blood counts, other toxicity, clinic attendance, and cost. Initial treatment depends on the transplant plan, biological risk, frailty, and organ function. A patient who can tolerate an intensive program may have a different prescription from someone who needs a reduced treatment burden. Ask what each medicine contributes, how long it is expected to continue, and what would trigger a dose change. The number of drugs alone is a poor comparison. A recent foreign authorization also needs a separate check against Chinese indications and hospital supply. EHA–EMN treatment guidance

6. Can an older adult still be considered for an autologous transplant?

Age is part of the assessment, but physical fitness, organ function, associated illnesses, infection risk, and available support also matter. An autologous transplant uses the patient's own stem cells. Collection, storage, conditioning, and recovery are separate steps, and transplant does not guarantee that all subsequent treatment will end. Even if transplantation is deferred, ask whether early collection should be considered to preserve future options. Families should understand the outpatient recovery requirements as well as the hospital stay. Leaving the ward does not necessarily mean the patient is ready for a long flight, independent living, or a full return to work. EBMT Handbook chapter on myeloma

7. When should worsening bone pain lead to an urgent assessment?

Sudden severe pain, inability to bear weight, new limb weakness, or a change in bladder or bowel function requires prompt assessment for fracture, instability, or nerve compression. Simply increasing pain medicine and waiting can miss a problem that needs an orthopedic or spinal response. Persistent but stable pain also deserves an explanation: an old fracture, an active lesion, and an unrelated musculoskeletal condition may need different approaches. Bracing, local radiation, fixation, or selected vertebral procedures can be considered alongside systemic treatment. A falling myeloma protein does not prove that damaged bone is mechanically safe, so activity advice should reflect the actual lesion. IMWG bone-disease recommendations

8. Can radiation replace myeloma medicines?

In multiple myeloma, radiation is generally used for a specific local purpose, such as pain relief or control of a threatening lesion. It does not automatically replace treatment of systemic disease. Solitary plasmacytoma is a distinct situation that requires staging to exclude more widespread involvement; having pain in only one place does not establish that diagnosis. If stem-cell collection is planned, the radiation and transplant teams should discuss the field and timing. External-beam treatment does not make the patient radioactive afterward, although fatigue, local reactions, and the underlying bone problem may still affect daily activity and travel arrangements. International Lymphoma Radiation Oncology Group guidance

9. Are effective treatments still possible when kidney function is poor?

Yes, and myeloma-related kidney injury can make rapid disease control especially important. The team needs to determine the cause and severity of the impairment, the speed of change, and the dose adjustments required. Not every abnormal kidney result has the same mechanism. Do not independently stop all antimyeloma medicines or follow a fixed instruction to drink large amounts of water; fluid plans may differ substantially with heart failure, dialysis, or fluid retention. Bring serial creatinine and light-chain results, urine studies, and dialysis records to China. They help hematology and nephrology teams judge what has happened rather than relying on a single recent measurement. IMWG renal-impairment recommendations

10. Does everyone need maintenance treatment for life?

Duration depends on the regimen, transplant history, disease risk, response, and tolerability. The 2026 ENDURANCE report compared fixed two-year lenalidomide maintenance with indefinite maintenance in standard-risk patients who did not undergo upfront transplantation. It did not find a statistically significant overall-survival difference between the groups. That does not prove the approaches are fully equivalent, and it cannot be transferred automatically to post-transplant care, high-risk disease, or every modern four-drug program. Ask which treatment phase you are in, whether there is a planned endpoint, and what monitoring would follow discontinuation. A news report is a reason for a clinic discussion, not an instruction to stop the prescription. ENDURANCE primary publication

11. Does a negative minimal residual disease result mean I am cured?

An MRD-negative result means no residual disease was detected by a particular test, at its stated sensitivity, in the sample examined at that time. It is valuable response information, but it is not a permanent guarantee about every site in the body. Sample quality, the test used, the duration of negativity, and disease outside the marrow can affect interpretation. Whether treatment can be reduced on this basis depends on the actual regimen and supporting evidence. Keep the method and sensitivity with the report rather than recording only “negative.” Results from different hospitals are most meaningful when the methods and clinical circumstances are sufficiently comparable. IMWG response and MRD criteria

12. Why can my doctor not give an exact number of years I will live?

Published outcomes describe groups treated in particular circumstances and periods. An individual's disease biology, response, later treatment options, and other illnesses can change the course. A more actionable conversation covers the response being sought now, the signs that would prompt a change, the prospects for regaining function, and the remaining options if control is lost. Depth of remission is not the only outcome that matters: infection, fractures, renal recovery, and ability to manage ordinary life should also be reviewed. Asking for one exact survival date can obscure these changing factors. It is reasonable to request an honest range of possibilities and an explanation of what remains uncertain. NCI professional treatment review

13. Does one rise in a protein result prove that treatment has failed?

The size and persistence of the change, the laboratory method, and any new organ damage need to be assessed. The doctor may also check treatment interruptions, dose reductions, infection, or interference in protein testing from a therapeutic monoclonal antibody. If relapse is confirmed, a detailed account of previous medicines, progression during specific drugs, and the length of earlier responses is more informative than the phrase “several treatments failed.” The urgency also differs: a slow biochemical trend is not managed in the same way as new kidney injury, significant symptoms of high calcium, or suspected nerve compression. Report new symptoms rather than waiting solely for the next scheduled protein test. IMWG relapsed-myeloma recommendations

14. How should patients compare CAR-T therapy with a bispecific antibody?

The practical pathways differ. CAR-T therapy requires cell collection and manufacturing, and treatment may be needed to control disease while waiting. A bispecific antibody does not generally require a patient-specific manufactured cell product, but initial step-up dosing and continuing infection prevention still require planning. Earlier exposure to a target can influence later treatment sequencing. Product-specific indications, the patient's current condition, and the center's capabilities determine whether an option is feasible. Response percentages from unrelated studies are not a sufficient comparison. Chinese cell products listed in national guidance and US-approved products should not be treated as interchangeable names with identical eligibility rules. Chinese National Health Commission guidance

15. Are medicines approved in 2026 suitable for every relapsed patient?

New authorizations usually specify previous treatment and a particular combination. For example, the US accelerated approval of iberdomide with daratumumab and dexamethasone in August 2026 does not establish equal benefit in every refractory setting. The supporting study excluded patients refractory to anti-CD38 treatment or bortezomib, and the approval evidence should not be described as mature proof of an overall-survival benefit. A Chinese treatment discussion must separately verify local authorization and supply. Bring the complete medication history and ask about a specific product in relation to that history. “Do you have the newest drug?” is less useful than identifying which evidence actually fits the person who would receive it. FDA iberdomide approval details

16. Which adverse effects should not wait for the next appointment?

Fever with significant illness, breathing difficulty, altered consciousness, uncontrolled bleeding, or a new serious neurological symptom should follow the urgent-care instructions provided by the treating team. After ciltacabtagene autoleucel, persistent diarrhea, abdominal pain, or weight loss can also warrant prompt review even weeks or months later. The FDA added a boxed warning for immune effector cell-associated enterocolitis. This does not mean every episode of diarrhea has that cause, but it should not be dismissed as a routine dietary problem. Carry the exact treatment name and administration date so local emergency clinicians can consider relevant complications while assessing other causes. FDA cellular-therapy safety update

17. Why is there no single reliable total price for treatment in China?

Initial induction, transplantation, long-term maintenance, and cellular therapy have different cost structures. Duration, dose calculations, complications, hospital time, and supportive care can change the bill. Request an itemized quotation in renminbi that identifies assessment, medicines, procedures, admission, monitoring, and any contingency allowance. It should state the period covered, exclusions, and circumstances that trigger revision. Foreign insurance rules and another patient's online bill do not establish your payment eligibility. When comparing hospitals, first make sure the estimates cover the same treatment stage and services. Without a defined clinical plan and a current hospital quotation, a nationwide personal total would be an unsupported number rather than a useful budget.

18. Does acceptance by a hospital mean I can immediately fly to China?

An appointment and medical suitability for travel are separate matters. Active infection, unstable breathing or circulation, an unaddressed fracture risk, or kidney injury needing urgent treatment may require local care before a journey. Travel assessment should consider recent blood counts, organ function, mobility, assistance, and the route, with communication between the local and receiving clinicians. The airline may have its own medical-clearance requirements. Do not interrupt antibiotics, dialysis, or effective ongoing treatment merely to meet an appointment date. If the planned therapy requires remaining near the treatment center for observation, arrange accommodation and a capable caregiver before booking the return journey. CDC guidance for travelers with chronic illness

19. What is most often missing from the plan after returning home?

A named local clinician and a usable handover can be more important than another general discharge summary. Before departure, obtain the medicines actually given, reasons for dose changes, latest disease measurements, infection-prevention instructions, and dates of upcoming tests. Confirm which tests and treatments are available near home. Bone strength, kidney function, and immune recovery may lag behind improvement in myeloma markers and need their own follow-up. Ongoing medication access also requires attention: a prescription issued in China does not automatically become a valid local prescription or permission to import the drug. Resolve refill responsibilities early enough to avoid an unintended gap in care. IMWG infection-prevention consensus

20. Are clinical trials only relevant after all other options have run out?

Trials can be appropriate at different stages. Their value depends on the research question, established alternatives, and the patient's circumstances. Ask about allocation to groups, which elements remain experimental, additional tests, time near the hospital, payment responsibilities, and care after withdrawal. A registry entry confirms that a study exists; it does not prove that a particular center currently has an available place. Formal screening can also exclude someone because of organ function, previous target-directed therapy, or timing requirements. Patients should understand these points before consenting. Declining or leaving a study should lead to a discussion of reasonable continuing care, not pressure to accept terms that remain unclear. NCI explanation of informed consent

Sources checked: September 9, 2026. This article provides general patient education; personal recommendations and local treatment access require individual confirmation.